AUGX Stock Overview
Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.60|
|52 Week High||US$6.22|
|52 Week Low||US$1.41|
|1 Month Change||-3.03%|
|3 Month Change||-28.89%|
|1 Year Change||-68.93%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-68.00%|
Recent News & Updates
Augmedix reports Q2 results
Augmedix press release (NASDAQ:AUGX): Q2 Revenue of $7.3M misses by $0.03M. Shares +11%. GAAP Net Loss was $7.4 million compared to $4.6 million. EBITDA losses were $6.8 million compared to $3.8 million. Adjusted EBITDA losses were $5.3 million compared to $4.0 million, which excludes the Stock-based compensation expense in both periods, the Loss on extinguishment of the prior debt facility in 2022, and the negotiated reduction of previously invoiced transaction-related expenses, related to the October 2020 transactions, and lease provision write-off in 2021. Cash and restricted cash as of June 30, 2022, was $30.8 million compared to $16.7 million as of June 30, 2021.
Augmedix: A Splendid Long-Term Investing Opportunity
Augmedix drives its revenue growth by reducing burnout of physicians who are highly productive. The company offers physicians medical note documentation service through its Notebuilder tool. Long-term investors can accumulate the company’s shares gradually during pullbacks to maximize their gain.
|AUGX||US Healthcare Services||US Market|
Return vs Industry: AUGX underperformed the US Healthcare Services industry which returned -44.1% over the past year.
Return vs Market: AUGX underperformed the US Market which returned -10.2% over the past year.
|AUGX Average Weekly Movement||12.1%|
|Healthcare Services Industry Average Movement||11.7%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: AUGX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: AUGX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live and Augmedix Notes solutions that provide pre-visit documentation, such as pre-charting and digitization of previous records/patient history; during-visit documentation, including medical notes, care gap reminders, HCC reminders, and after-visit summaries; and post-visit documentation consisting of coding, orders, and referrals. The company enables clinicians to access its applications through mobile devices, such as smartphones or Google Glass.
Augmedix Fundamentals Summary
|AUGX fundamental statistics|
Is AUGX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AUGX income statement (TTM)|
|Cost of Revenue||US$14.72m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.58|
|Net Profit Margin||-81.80%|
How did AUGX perform over the long term?See historical performance and comparison
Is AUGX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AUGX?
Other financial metrics that can be useful for relative valuation.
|What is AUGX's n/a Ratio?|
Price to Sales Ratio vs Peers
How does AUGX's PS Ratio compare to its peers?
|AUGX PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
Price-To-Sales vs Peers: AUGX is good value based on its Price-To-Sales Ratio (2.3x) compared to the peer average (12.7x).
Price to Earnings Ratio vs Industry
How does AUGX's PE Ratio compare vs other companies in the US Healthcare Services Industry?
Price-To-Sales vs Industry: AUGX is good value based on its Price-To-Sales Ratio (2.3x) compared to the US Healthcare Services industry average (2.9x)
Price to Sales Ratio vs Fair Ratio
What is AUGX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||2.3x|
|Fair PS Ratio||3x|
Price-To-Sales vs Fair Ratio: AUGX is good value based on its Price-To-Sales Ratio (2.3x) compared to the estimated Fair Price-To-Sales Ratio (3x).
Share Price vs Fair Value
What is the Fair Price of AUGX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate AUGX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate AUGX's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Augmedix forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AUGX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AUGX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AUGX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AUGX's revenue (28.5% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: AUGX's revenue (28.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AUGX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Augmedix performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AUGX is currently unprofitable.
Growing Profit Margin: AUGX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AUGX is unprofitable, but has reduced losses over the past 5 years at a rate of 4.3% per year.
Accelerating Growth: Unable to compare AUGX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AUGX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (2.8%).
Return on Equity
High ROE: AUGX has a negative Return on Equity (-194.26%), as it is currently unprofitable.
Discover strong past performing companies
How is Augmedix's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: AUGX's short term assets ($36.4M) exceed its short term liabilities ($12.6M).
Long Term Liabilities: AUGX's short term assets ($36.4M) exceed its long term liabilities ($16.8M).
Debt to Equity History and Analysis
Debt Level: AUGX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if AUGX's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AUGX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AUGX has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 0.8% each year.
Discover healthy companies
What is Augmedix current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AUGX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AUGX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AUGX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AUGX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AUGX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Manny Krakaris (63 yo)
Mr. Emmanuel Krakaris, also known as Manny, is President, Chief Executive Officer, Secretary and Director of Augmedix, Inc. since October 2018. Mr. Krakaris served as the Chief Executive Officer and Presid...
CEO Compensation Analysis
Compensation vs Market: Manny's total compensation ($USD1.76M) is above average for companies of similar size in the US market ($USD759.98K).
Compensation vs Earnings: Manny's compensation has increased whilst the company is unprofitable.
Experienced Management: AUGX's management team is considered experienced (3.3 years average tenure).
Experienced Board: AUGX's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AUGX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 38%.
Augmedix, Inc.'s employee growth, exchange listings and data sources
- Name: Augmedix, Inc.
- Ticker: AUGX
- Exchange: NasdaqCM
- Founded: 2013
- Industry: Health Care Technology
- Sector: Healthcare
- Implied Market Cap: US$59.874m
- Shares outstanding: 37.42m
- Website: https://www.augmedix.com
Number of Employees
- Augmedix, Inc.
- 111 Sutter Street
- Suite 1300
- San Francisco
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/15 00:00|
|End of Day Share Price||2022/08/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.